Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 1 of 1 (100%) have an AI response strategy ready
Signablok Inc. is active in the Biotechnology & Pharmaceuticals technology area. The company's patent portfolio currently includes 1 pending office action. This prosecution activity is confined to 1 distinct examiner and 1 distinct art unit. The involvement of 1 distinct art unit indicates that the subject matter of the pending application is specialized within the biotechnology field. This concentration allows the company to focus its resources on a single point of contact at the USPTO.
The busiest examiner identified in the data is LEE, JIA-HAI, who is overseeing 1 busiest examiner pending office action. This examiner handles the 1 pending office action that makes up the company's current workload. For a practitioner, this means that the prosecution strategy is entirely centered on the feedback from LEE, JIA-HAI. The fact that there is 1 pending office action suggests a period of limited but critical examination. Navigating this process effectively requires a thorough understanding of the specific examiner's technical expectations and examination style within the biotech sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEE, JIA-HAI | 1 | 49.0% | +46.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16719103 | Inhibition Of TCR Signaling With Peptide Variants | LEE, JIA-HAI | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 16719103 | Inhibition Of TCR Signaling With Peptide Variants | LEE, JIA-HAI | 1658 | §112 | Non-Final OA | — | AI Ready | Dec 18, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSignablok Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jia-Hai Lee has the most, with 1 of Signablok Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
